




RealRate

PHARMACEUTICAL 2020

Seres Therapeutics Inc.
Rank 305 of 358





RealRate

PHARMACEUTICAL 2020

Seres Therapeutics Inc.
Rank 305 of 358



The relative strengths and weaknesses of Seres Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Seres Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 20% points. The greatest weakness of Seres Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 110% points.

The company's Economic Capital Ratio, given in the ranking table, is -98%, being 134% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	100,189
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	45,993
Liabilities, Non-Current	21,012
Other Assets	12,756
Other Compr. Net Income	0
Other Expenses	1,492
Other Liabilities	113,759
Other Net Income	1,597
Other Revenues	34,505
Property and Equipment	19,495
Research and Development	80,141
Selling, General and Administrative Expense	24,748

Output Variable	Value in 1000 USD
Assets	132,440
Liabilities	180,764
Expenses	106,381
Revenues	34,505
Stockholders Equity	-48,324
Net Income	-70,279
Comprehensive Net Income	-70,279
Economic Capital Ratio	-98%